Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
K.S. Tølbøl
Observed names:
KIRSTINE SLOTH TØLBØL,
Kirstine S Tølbøl,
Kirstine S. Tølbøl,
Kirstine Sloth Tølbøl,
Kirstine Tølbøl,
Kirstine Tølbøl Thrane
show all 6
Institution:
Gubra (Denmark)
Observed institutions:
University of Copenhagen,
Lundbeck (Denmark),
Novo Nordisk Foundation,
Gubra (Denmark),
Intercept Pharmaceuticals (United States)
OpenAlex ID:
A5066580974
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
2019
·
Michelle L Boland
, Denise Oró
, et al.
·
World Journal of Gastroenterology
·
147
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis
2018
·
Kirstine S Tølbøl
, Maria NB Kristiansen
, et al.
·
World Journal of Gastroenterology
·
140
Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy
2016
·
Maria Nicoline Baandrup Kristiansen
, Sanne Skovgård Veidal
, et al.
·
World Journal of Hepatology
·
126
PDF
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH
2022
·
Mathias B. Møllerhøj
, Sanne S. Veidal
, et al.
·
Clinical and Translational Science
·
88
PDF
Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission
2018
·
Alan L. Pehrson
, Christian S. Pedersen
, et al.
·
Frontiers in Pharmacology
·
31
PDF
Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis
2018
·
Kirstine S. Tølbøl
, Birgit Stierstorfer
, et al.
·
Digestive Diseases and Sciences
·
24
PDF
YH25724, a novel long-acting GLP-1/FGF21 dual agonist lowers both non-alcoholic fatty liver disease activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
2017
·
H.N. Hong
, J.H. Kim
, et al.
·
Journal of Hepatology
·
9
YH25724, a novel long-acting GLP-1/FGF21 dual agonist improves hepatic steatosis, inflammation and fibrosis in nonalcoholic steatohepatitis (NASH) animal models
2016
·
Jun Hwan Kim
, Han Hong
, et al.
·
3
MET409, a potent, non-bile acid sustained FXR agonist, improves NAFLD activity score and exerts anti-fibrotic effects in a diet-induced obese mouse model of biopsy-confirmed fibrosing NASH
2020
·
Sanne Veidal
, Michael Feigh
, et al.
·
Journal of Hepatology
·
2
2020-P: Comparable Disease Progression in GAN and AMLN Diet-Induced Obese Mouse Models of Biopsy-Confirmed Nonalcoholic Steatohepatitis
2019
·
BRANDON B. BOLAND
, HENRIK H. HANSEN
, et al.
·
Diabetes
·
2
Comparative effects of liraglutide, elafibranor and obeticholic acid on NAFLD activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed NASH
2017
·
M. Feigh
, K.S. Tølbøl
, et al.
·
Journal of Hepatology
·
2
FRI-354-Novel Gubra Amylin NASH diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
2019
·
Sanne Veidal
, Michael Feigh
, et al.
·
Journal of Hepatology
The effect of elafibranor and obeticholic acid on NAFLD Activity score and fibrosis stage in a novel metabolic rat model of diet-induced and biopsy-confirmed NASH
2017
·
N. Vrang
, K.S. Tølbøl
, et al.
·
Journal of Hepatology
Show more works
View as search
Works count:
13
Citation count:
574
H-index:
7
I10-index:
6
Year
Topic
Type